Evidence map›Paper›PMID 25411964›Full record

ArticlePloS one2014

Overexpression of forkhead box protein M1 (FOXM1) in ovarian cancer correlates with poor patient survival and contributes to paclitaxel resistance.

Fung Zhao, Michelle K Y Siu, LiLi Jiang, Kar Fai Tam, Hextan Y S Ngan, Xiao Feng Le, Oscar G W Wong, Esther S Y Wong, Ana R Gomes, Laura Bella and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed, 4 pooled it
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 4 syntheses or guidelines pooled it, 88 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Mechanisms of cancer cell death induction by paclitaxel: an updated review.Apoptosis : an international journal on programmed cell death · 2022
    Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 4 countries.

Fung ZhaoDepartment of Pathology, The University of Hong Kong, HKSAR, China; Department of Surgery and Cancer, Imperial College London, London, United Kingdom.
Michelle K Y SiuObstetrics and Gynaecology, The University of Hong Kong, HKSAR, China.
LiLi JiangDepartment of Pathology, West China Hospital, Sichuang University, Chengdu, China.
Kar Fai TamDepartment of Pathology, The University of Hong Kong, HKSAR, China.
Hextan Y S NganObstetrics and Gynaecology, The University of Hong Kong, HKSAR, China.
Xiao Feng LeDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Texas, United States of America.
Oscar G W WongDepartment of Pathology, The University of Hong Kong, HKSAR, China.
Esther S Y WongDepartment of Pathology, The University of Hong Kong, HKSAR, China.
Ana R GomesDepartment of Surgery and Cancer, Imperial College London, London, United Kingdom.
Laura BellaDepartment of Surgery and Cancer, Imperial College London, London, United Kingdom.
Pasarat KhongkowDepartment of Surgery and Cancer, Imperial College London, London, United Kingdom.
Eric W-F LamDepartment of Surgery and Cancer, Imperial College London, London, United Kingdom.
Annie N Y CheungDepartment of Pathology, The University of Hong Kong, HKSAR, China; Department of Pathology, The University of Hong Kong -Shenzhen Hospital, Shenzhen, China.
University of Hong Kong · HKImperial College London · GBThe University of Texas MD Anderson Cancer Center · USUniversity of Hong Kong - Shenzhen Hospital · CNWest China Hospital of Sichuan University · CN

Funding

Biotechnology and Biological Sciences Research Council BBS/B/03785Breast Cancer Now 2012MAYPR070Breast Cancer Now 2012NOVPHD016Cancer Research UK
6 · The paper itself

Abstract

aimDeregulation of FOXM1 has been documented in various cancers. The aim of this study was to evaluate the role of FOXM1 in ovarian cancer tumorigenesis and paclitaxel resistance. EXPERIMENTAL

designExpression of FOXM1 was examined in 119 clinical samples by immunohistochemistry and correlated with clinicopathological parameters. Effects of FOXM1 knockdown on ovarian cancer cell migration, invasion and mitotic catastrophe were also studied. qPCR and ChIP-qPCR were used to establish KIF2C as a novel FOXM1 target gene implicated in chemoresistance.

resultsHigh nuclear FOXM1 expression in ovarian cancer patient samples was significantly associated with advanced stages (P = 0.035), shorter overall (P = 0.019) and disease-free (P = 0.014) survival. Multivariate analysis confirmed FOXM1 expression as an independent prognostic factor for ovarian cancer. FOXM1 knockdown significantly inhibited migration and invasion of ovarian cancer cells and enhanced paclitaxel-mediated cell death and mitotic catastrophe in a p53-independent manner. Bioinformatics analysis suggested a number of potential transcription targets of FOXM1. One of the potential targets, KIF2C, exhibited similar expression pattern to FOXM1 in chemosensitive and chemoresistant cells in response to paclitaxel treatment. FOXM1 could be detected at the promoter of KIF2C and FOXM1 silencing significantly down-regulated KIF2C.

conclusionOur findings suggest that FOXM1 is associated with poor patient outcome and contributes to paclitaxel resistance by blocking mitotic catastrophe. KIF2C is identified as a novel FOXM1 transcriptional target that may be implicated in the acquisition of chemoresistance. FOXM1 should be further investigated as a potential prognostic marker and therapeutic target for ovarian cancer.

Indexed as

Antineoplastic Agents, PhytogenicApoptosisCell Line, TumorCell MovementDisease-Free SurvivalDown-RegulationDrug Resistance, NeoplasmFemaleFollow-Up StudiesForkhead Box Protein M1Forkhead Transcription FactorsG2 Phase Cell Cycle CheckpointsHumansImmunohistochemistryKaplan-Meier EstimateKinesinsAntineoplastic Agents, PhytogenicForkhead Box Protein M1Forkhead Transcription FactorsFOXM1 protein, humanKIF2C protein, humanKinesinsPaclitaxel

Identifiers

PMID25411964
PMCPMC4239070
OpenAlexW1971577144

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.